Aptamer: A potential oligonucleotide nanomedicine in the diagnosis and treatment of hepatocellular carcinoma
Metrics: HTML 1472 views | ?
Rusdina Bte Ladju1,2, Devis Pascut1, Muhammad Nasrum Massi2, Claudio Tiribelli1 and Caecilia H.C. Sukowati1
1Fondazione Italiana Fegato, AREA Science Park Basovizza, Trieste, Italy
2Faculty of Medicine, Hasanuddin University, Makassar, Indonesia
Caecilia H.C. Sukowati, email: email@example.com
Keywords: hepatocellular carcinoma; aptamer; oligonucleotide nanomedicine; future therapy
Received: October 10, 2017 Accepted: December 01, 2017 Published: December 16, 2017
Hepatocellular carcinoma (HCC) is one of the most common cancers with a high mortality rate. Late diagnosis and poor prognosis are still a major drawback since curative therapies such as liver resection and liver transplantation are effective only for an early stage HCC. Development of novel molecular targeting therapies against HCC may provide new options that will improve the efficiency of the diagnosis and the success of the therapy, thus ameliorating the life expectancy of the patients. The aptamer is an oligonucleotide nanomedicine that has high binding affinity and specificity to small and large target molecules in the intracellular and extracellular environment with agonist or antagonist function. Currently, several aptamers for diagnostic and therapeutic purposes are under development to recognize different molecules of HCC. In in vitro models, the aptamer has been shown to be able to reduce the growth of HCC cells and increase the sensitivity to conventional chemotherapies. In in vivo mouse models, aptamer could induce cell apoptosis with antitumor activity. Overall data had shown that aptamer has limited toxicity and might be safe in clinical application. This review summarizes recent information of aptamer as a potential oligonucleotide nanomedicine tool, in diagnostics, targeted therapy, and as drug delivery nano-vehicles.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.